Genetic testing

Sysmex and Hitachi High-Tech Agree to Collaborate on Development of New Genetic Testing Systems

Retrieved on: 
Thursday, February 8, 2024

TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).

Key Points: 
  • TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).
  • To achieve widespread clinical realization, Sysmex and Hitachi High-Tech will develop more efficient genetic testing systems at a lower cost, aiming at expanding optimal genetic testing for individual diseases.
  • In recent years, there has been active development of assay reagents using next generation sequencer (NGS)(2) in the genetic testing field.
  • Having achieved the milestones in the FS agreement, Sysmex and Hitachi High-Tech have agreed, as the next step, to collaborate on the development of genetic testing systems with a view to their widespread adoption in the clinical setting.

ProCure Addresses Projected Rise in Cancer Rates, Encourages Proactive Screening for Early Detection

Retrieved on: 
Tuesday, February 6, 2024

Doctors at ProCure Proton Therapy Center say the news reinforces the need to stay updated on cancer screenings.

Key Points: 
  • Doctors at ProCure Proton Therapy Center say the news reinforces the need to stay updated on cancer screenings.
  • "Early detection is paramount in the battle against cancer," said Dr. Brian Chon, medical director at ProCure.
  • One of the more concerning areas of the report highlights the rise in cancer among younger patients.
  • Early detection of cancer enables patients to explore advanced treatment options, such as proton therapy.

Parkinson's Foundation to Accelerate Research Through Expanded Genetic Testing and Counseling Study

Retrieved on: 
Tuesday, February 6, 2024

NEW YORK and MIAMI, Feb. 6, 2024 /PRNewswire/ -- Through its Global Parkinson's Genetics Program (GP2), Aligning Science Across Parkinson's (ASAP) has awarded the Parkinson's Foundation a grant that will significantly expand its landmark international genetics study, PD GENEration: Mapping the Future of Parkinson's Disease. The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD). ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.

Key Points: 
  • The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD).
  • ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.
  • It is a patient-facing research study," said Parkinson's Foundation Senior Vice President and Chief Scientific Officer James Beck, PhD.
  • Fox Foundation for Parkinson's Research is ASAP's implementation partner and issued the grants on behalf of ASAP and GP2.

Gattaca Genomics Leads the Way in Revolutionizing Fertility with Artificial Intelligence for Full Genome Analysis, Including Preimplantation Genetic Testing and Genetic Counseling

Retrieved on: 
Tuesday, February 6, 2024

By integrating advanced artificial intelligence (AI) technologies the company aspires to enhance the success rates of fertility procedures.

Key Points: 
  • By integrating advanced artificial intelligence (AI) technologies the company aspires to enhance the success rates of fertility procedures.
  • Utilizing sophisticated hyperparameter turning and deep learning, Gattaca Genomics develops precise genetic analysis, identifying anomalies and patterns with unparalleled accuracy.
  • Harnessing the power of large language models (LLM), Gattaca Genomics transforms the landscape of genetic counseling in assisted reproductive processes.
  • Gattaca Genomics integrates expert, independent, board-certified genetic counseling services seamlessly into its AI-driven genetic testing process.

Global Sequencing Kits Market Analysis Report 2023-2030: Market Driven by Rising Prevalence of Genetic Disorders, Genome Mapping Programs and Decreasing Sequencing Costs Propel Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, February 5, 2024

The "Sequencing Kits Market by Type Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sequencing Kits Market by Type Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global sequencing kits market is projected to reach $21.9 billion by 2030, at a CAGR of 15.3% from 2023 to 2030.
  • However, the high costs of sequencing kits & reagents and the ethical & legal issues related to DNA sequencing-based diagnosis are factors restraining the growth of this market.
  • Additionally, developing portable sequencing technologies and increasing partnerships & collaborations among NGS product manufacturers to expand and improve product offerings are prominent trends in the sequencing kits & reagents market.

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Retrieved on: 
Thursday, February 1, 2024

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.

Key Points: 
  • SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.
  • Myriad’s Precise Tumor Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes a patient’s tumor DNA to discover and target important variants within tumors.
  • Myriad will operate TheraMap: Solid Tumor solely as Precise Tumor moving forward.
  • Precise Liquid, which is expected to launch later this year, will provide convenient comprehensive genomic profiling results from a blood draw.

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Retrieved on: 
Tuesday, January 30, 2024

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.

Key Points: 
  • SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.
  • Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients.
  • He is an accomplished healthcare leader with a proven ability to spearhead and manage the development of precision medicine and clinical research programs in the oncology space,” said Paul J. Diaz, president and CEO, Myriad Genetics.
  • “We are delighted for George to join Myriad to lead our oncology commercial and clinical strategy as we continue to expand our oncology portfolio,” said Mark Verratti, Chief Commercial Officer, Myriad Genetics.

Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome

Retrieved on: 
Wednesday, January 31, 2024

Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).

Key Points: 
  • Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).
  • JAG201 aims to deliver functional SHANK3 via the AAV9 vector to treat the root cause of the disease.
  • “We are pleased to receive FDA clearance to bring our investigational SHANK3 gene therapy to the clinic.
  • The pre-clinical data indicate that JAG201 may have the potential to be transformative for those suffering with the disorder,” said Joe Nolan, chief executive officer of Jaguar Gene Therapy.

CancerIQ Names Genetics Industry Veteran Diedre Mavin Senatra As Senior Vice President of Commercial Strategy

Retrieved on: 
Thursday, February 1, 2024

CHICAGO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- CancerIQ, the platform enabling health systems to use genetic information to prevent, detect, and treat cancer at scale, announced today that industry leader Diedre Mavin Senatra has joined the team as Senior Vice President of Commercial Strategy.

Key Points: 
  • Senatra joins CancerIQ at a critical time, as providers must update protocols to meet expanded industry guidelines for cancer risk assessment and genetic testing — and are increasingly seeking out CancerIQ as a solution.
  • CHICAGO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- CancerIQ , the platform enabling health systems to use genetic information to prevent, detect, and treat cancer at scale, announced today that industry leader Diedre Mavin Senatra has joined the team as Senior Vice President of Commercial Strategy.
  • Senatra joins CancerIQ at a critical time, as providers must update protocols to meet expanded industry guidelines for cancer risk assessment and genetic testing — and are increasingly seeking out CancerIQ as a solution.
  • Senatra is well-respected in the hereditary cancer genetics and genomics industry.

Removing Barriers: Susan G. Komen® Launches Stand for H.E.R - A Health Equity Revolution Impact Report

Retrieved on: 
Tuesday, January 30, 2024

DALLAS, Jan. 30, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, has launched the Stand for H.E.R. – A Health Equity Revolution Breast Cancer Impact Report. This transformative report not only exposes the stark breast cancer health disparities faced by Black women in the United States, but also details Komen's concerted efforts to help dismantle these barriers and foster community relationships to create systemic change.

Key Points: 
  • DALLAS, Jan. 30, 2024 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, has launched the Stand for H.E.R.
  • – A Health Equity Revolution Breast Cancer Impact Report .
  • – A Health Equity Revolution Breast Cancer Impact Report.
  • For more information on Komen's efforts to close the breast cancer health equity gap for the Black community and make quality care available to all, visit www.komen.org/standforher .